Literature DB >> 18637518

Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing.

D N Streblow1, J Dumortier, A V Moses, S L Orloff, J A Nelson.   

Abstract

Human cytomegalovirus (HCMV) is associated with the acceleration of a number of vascular diseases such as atherosclerosis, restenosis, and transplant vascular sclerosis (TVS). All of these diseases are the result of either mechanical or immune-mediated injury followed by inflammation and subsequent smooth muscle cell (SMC) migration from the vessel media to the intima and proliferation that culminates in vessel narrowing. A number of epidemiological and animal studies have demonstrated that CMV significantly accelerates TVS and chronic rejection (CR) in solid organ allografts. In addition, treatment of human recipients and animals alike with the antiviral drug ganciclovir results in prolonged survival of the allograft, indicating that CMV replication is a requirement for acceleration of disease. However, although virus persists in the allograft throughout the course of disease, the number of directly infected cells does not account for the global effects that the virus has on the acceleration of TVS and CR. Recent investigations of up- and downregulated cellular genes in infected allografts in comparison to native heart has demonstrated that rat CMV (RCMV) upregulates genes involved in wound healing (WH) and angiogenesis (AG). Consistent with this result, we have found that supernatants from HCMV-infected cells (HCMV secretome) induce WH and AG using in vitro models. Taken together, these findings suggest that one mechanism for HCMV acceleration of TVS is mediated through induction of secreted cytokines and growth factors from virus-infected cells that promote WH and AG in the allograft, resulting in the acceleration of TVS. We review here the ability of CMV infection to alter the local environment by producing cellular factors that act in a paracrine fashion to enhance WH and AG processes associated with the development of vascular disease, which accelerates chronic allograft rejection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637518      PMCID: PMC2699259          DOI: 10.1007/978-3-540-77349-8_22

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  61 in total

Review 1.  Choroidal neovascularization: a wound healing perspective.

Authors:  David Kent; Carl Sheridan
Journal:  Mol Vis       Date:  2003-12-22       Impact factor: 2.367

Review 2.  A review on pro- and anti-angiogenic factors as targets of clinical intervention.

Authors:  Diane Bouïs; Yoka Kusumanto; Coby Meijer; Nanno H Mulder; Geke A P Hospers
Journal:  Pharmacol Res       Date:  2006-02       Impact factor: 7.658

3.  Increased urinary excretion of transforming growth factor-beta(1) in renal transplant recipients during cytomegalovirus infection.

Authors:  Ilkka Helanterä; Anna-Maija Teppo; Petri Koskinen; Tom Törnroth; Carola Grönhagen-Riska; Irmeli Lautenschlager
Journal:  Transpl Immunol       Date:  2005-12-22       Impact factor: 1.708

4.  Rat cytomegalovirus gene expression in cardiac allograft recipients is tissue specific and does not parallel the profiles detected in vitro.

Authors:  Daniel N Streblow; Koen W R van Cleef; Craig N Kreklywich; Christine Meyer; Patricia Smith; Victor Defilippis; Finn Grey; Klaus Früh; Robert Searles; Cathrien Bruggeman; Cornelis Vink; Jay A Nelson; Susan L Orloff
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

5.  Persistent cytomegalovirus infection is associated with increased expression of TGF-beta1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts.

Authors:  Ilkka Helanterä; Raisa Loginov; Petri Koskinen; Tom Törnroth; Carola Grönhagen-Riska; Irmeli Lautenschlager
Journal:  Nephrol Dial Transplant       Date:  2005-02-16       Impact factor: 5.992

6.  T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease.

Authors:  Wenwei Tu; Luciano Potena; Pamela Stepick-Biek; Lanxiang Liu; Kira Y Dionis; Helen Luikart; William F Fearon; Tyson H Holmes; Clifford Chin; John P Cooke; Hannah A Valantine; Edward S Mocarski; David B Lewis
Journal:  Circulation       Date:  2006-10-02       Impact factor: 29.690

7.  Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination.

Authors:  Satoshi Noda; Shirley A Aguirre; Andrew Bitmansour; Janice M Brown; Timothy E Sparer; Jing Huang; Edward S Mocarski
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

8.  Cytomegalovirus accelerates chronic allograft nephropathy in a rat renal transplant model with associated provocative chemokine profiles.

Authors:  J L Soule; D N Streblow; T F Andoh; C N Kreklywich; S L Orloff
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

9.  Human cytomegalovirus-induced reduction of extracellular matrix proteins in vascular smooth muscle cell cultures: a pathomechanism in vasculopathies?

Authors:  Barbara Reinhardt; Michael Winkler; Peter Schaarschmidt; Robert Pretsch; Shaoxia Zhou; Bianca Vaida; Alexandra Schmid-Kotsas; Detlef Michel; Paul Walther; Max Bachem; Thomas Mertens
Journal:  J Gen Virol       Date:  2006-10       Impact factor: 3.891

10.  Cytomegalovirus enhance expression of growth factors during the development of chronic allograft nephropathy in rats.

Authors:  Kaija Inkinen; Anu Soots; Leena Krogerus; Raisa Loginov; Cathrien Bruggeman; Irmeli Lautenschlager
Journal:  Transpl Int       Date:  2005-06       Impact factor: 3.782

View more
  57 in total

Review 1.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

Review 2.  The role of cytomegalovirus in angiogenesis.

Authors:  Patrizia Caposio; Susan L Orloff; Daniel N Streblow
Journal:  Virus Res       Date:  2010-10-01       Impact factor: 3.303

3.  Human Cytomegalovirus UL135 and UL136 Genes Are Required for Postentry Tropism in Endothelial Cells.

Authors:  Farah Bughio; Mahadevaiah Umashankar; Jean Wilson; Felicia Goodrum
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes.

Authors:  Gary Chan; Maciej T Nogalski; Gretchen L Bentz; M Shane Smith; Alexander Parmater; Andrew D Yurochko
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

5.  Incidence of cytomegalovirus infection in Shanghai, China.

Authors:  Feng-Qin Fang; Qi-Shi Fan; Zhi-Jun Yang; Yi-Bing Peng; Li Zhang; Ke-Zi Mao; Yue Zhang; Yu-Hua Ji
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

Review 6.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

7.  Cellular distribution of CD200 receptor in rats and its interaction with cytomegalovirus e127 protein.

Authors:  Mohamed A El-Mokhtar; Agnieszka Bauer; Julia Madela; Sebastian Voigt
Journal:  Med Microbiol Immunol       Date:  2018-07-21       Impact factor: 3.402

8.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

9.  The Impact of Mass Spectrometry-Based Proteomics on Fundamental Discoveries in Virology.

Authors:  Todd M Greco; Benjamin A Diner; Ileana M Cristea
Journal:  Annu Rev Virol       Date:  2014-07-14       Impact factor: 10.431

10.  Human cytomegalovirus UL29/28 protein interacts with components of the NuRD complex which promote accumulation of immediate-early RNA.

Authors:  Scott S Terhune; Nathaniel J Moorman; Ileana M Cristea; John Paul Savaryn; Christian Cuevas-Bennett; Michael P Rout; Brian T Chait; Thomas Shenk
Journal:  PLoS Pathog       Date:  2010-06-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.